Marksans Pharma Ltd.

Annexure B1

Format of the Annual Disclosure to be made by an entity identified as a Large Corporate

1. Name of the Company: Marksans Pharma Limited

2. CIN: L24110MH1992PLC066364

3. Report filed for FY: FY 2020-21

4. Details of the borrowings (all figures in Rs. Crore)

Sr. No.	Particulars	Details
i	Incremental borrowing done in FY (a)	Nil
ii	Mandatory borrowing to be done through issuance of debt securities ((b) = (25% of a)	Not Applicable
iii	Actual borrowings done through debt securities in FY (c)	Nil
iv	Shortfall in the mandatory borrowing through debt securities if any (d) = (b) – (c) {If the calculated value is zero or negative, write nil}	Not Applicable
V	Reasons for shortfall, if any, in mandatory borrowings through debt securities	Not Applicable

Note: We are not a Large Corporate as per the applicability criteria given under the SEBI Circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018.

Harshavardhan Panigrahi
Company Secretary
Marksans Pharma Limited

E-mail: harshavardhan@marksanspharma.com
Mobile: 9833982246

Jitendra Sharma
Chief Financial Officer
Marksans Pharma Limited

jitendra@marksanspharma.com
9820338507

Date : 7th April, 2021